Stockscreener 앱 받기
0.635
2.25%
-0.0146
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTI stock touches 52-week low at $0.65 amid market challenges By Investing.com - Investing.com South Africa
KPTI stock touches 52-week low at $0.65 amid market challenges - Investing.com Canada
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Karyopharm Therapeutics Inc.'s SWOT analysis: oncology firm's stock faces pivotal trials - Investing.com
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - The Eastern Progress Online
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - Kilgore News Herald
Karyopharm Appoints Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - citybiz
Karyopharm CEO Richard Paulson sells $2,932 in stock By Investing.com - Investing.com Nigeria
Karyopharm CEO Richard Paulson sells $2,932 in stock - Investing.com
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - Defense World
Karyopharm Engages with FDA on Cancer Trial Plans - TipRanks
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short Interest - MarketBeat
Karyopharm reports inducement grants under Nasdaq listing rule - TipRanks
Karyopharm Therapeutics Awards 4,800 RSUs to New Employees in Retention Plan - StockTitan
Karyopharm Therapeutics (STU:25K) Operating Cash Flow per S - GuruFocus.com
KPTI (Karyopharm Therapeutics) Market Cap : $109.8 Mil (As of Nov. 26, 2024) - GuruFocus.com
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com - Defense World
Karyopharm Therapeutics' SWOT analysis: oncology stock faces pivotal trials - Investing.com
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.
Karyopharm Therapeutics to Present at Piper Sandler Healthcare Conference | KPTI Stock News - StockTitan
Karyopharm appoints new chief accounting officer By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm appoints new chief accounting officer - Investing.com India
Karyopharm Therapeutics Appoints Kristin Abate Chief Accounting Officer - citybiz
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer - Citizentribune
Karyopharm Therapeutics Appoints New Chief Accounting Officer - TipRanks
Karyopharm appoints Kristin Abate as Chief Accounting Officer - TipRanks
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire
Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat
GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):